BioAge Labs, Inc.

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for metabolic diseases by targeting the biology of human aging. Its lead program, BGE-102, is aimed at obesity and other metabolic conditions, with a stated goal of creating treatments that complement GLP-1 agonists and address unmet needs such as oral combination therapy. The company also uses longitudinal human aging datasets and a discovery platform to identify and validate novel therapeutic targets. BioAge has no approved products and does not yet generate product sales, so its business model currently depends on research collaboration revenue, external funding, and future clinical success.

−1 029,2 %

−896,1 %

14.24

14.24

— BioAge Labs, Inc.
%
Lead product candidate0% BGE-102 and related development work aimed at metabolic disease indications, including obesity.
Discovery platform and target validation0% Human aging data analytics used to identify and validate novel therapeutic targets.
Collaborative research agreements100% Partnerships such as the Novartis and Lilly collaborations that fund discovery work and may generate milestones and royalties.
Preclinical and clinical development services0% Internal and outsourced R&D activities supporting candidate advancement through early-stage testing.

BioAge does not currently sell approved medicines to end customers; instead, its near-term counterparties are...

  • Pharmaceutical collaboration partnersprimary

    Large pharma companies that pay for target discovery, validation, and optional licensing rights because BioAge's aging datasets can surface differentiated metabolic disease targets.

  • Future commercialization partnerssecondary

    Potential licensees or co-marketing partners that would help fund late-stage development and market approved products if BioAge does not build its own sales force.

  • Healthcare providers and payorsemerging

    Physicians, hospitals, and reimbursement decision-makers that would influence adoption of any approved obesity or metabolic disease therapy.

  • Patients with metabolic diseaseemerging

    End users for any approved therapy, especially obesity and related metabolic disease patients seeking differentiated treatment options.

BioAge is headquartered in the United States and operates as a U.S.-based clinical-stage biotech company...

  • •United States headquarters and primary operating base
  • •Emeryville, California office and lab lease through 2031
  • •Third-party manufacturing in China and India
  • •Global collaboration and licensing model rather than local sales footprint
  • •Future commercialization geography depends on product approvals and partners

BioAge's strategy is to use human aging biology and longitudinal datasets to discover targets that can produce...

01
Advance BGE-102short-term

The lead candidate is the most direct path to clinical value creation and future product revenue.

02
Expand target discovery partnershipsshort-term

Collaborations such as Novartis and Lilly provide funding, validation, and optional downstream economics while reducing sole reliance on one program.

03
Broaden the pipeline from the aging platformmedium-term

A wider pipeline improves the odds of finding commercially viable metabolic disease assets and diversifies scientific risk.

04
Prepare commercialization optionalitymedium-term

If a candidate is approved, the company needs either a partner or its own sales and marketing capabilities to capture value.

BioAge faces the classic risks of a clinical-stage biotech: no approved products, no product revenue, and heavy...

high

Clinical development failure

BGE-102 and future candidates may not demonstrate sufficient safety or efficacy to advance, which would eliminate the main path to product revenue.

Scope
Lead asset and pipeline
Materiality
high
high

Third-party manufacturing and supply chain disruption

The company relies on external manufacturers in China and India, so production issues, tariffs, or geopolitical events could delay trials or commercialization.

Scope
Preclinical and clinical supply
Materiality
high
high

Funding and dilution risk

The company remains loss-making and depends on capital markets and collaboration funding to sustain R&D.

Scope
Corporate financing
Materiality
high
medium

Commercialization capability gap

BioAge has no sales or marketing infrastructure and no prior commercialization experience, making post-approval execution uncertain.

Scope
Future approved products
Materiality
high
medium

Intellectual property disputes

Patent challenges or third-party infringement claims could require costly litigation or licensing and reduce economics from approved products.

Scope
Platform and product candidates
Materiality
medium
Collaboration revenue under ASC 606
Novartis deferred revenue and quarterly collaboration revenue
Deferred revenue
Balance sheet liabilities and future revenue timing
R&D cost accruals and outsourced development spend
Operating expenses and net loss
Lease accounting
Balance sheet lease liability and G&A expense
Fair value measurement of warrants and financing instruments
Other income (expense), net

BIOVIE INC.

BIVI · Pharmaceutical Preparations

BIO-PATH HOLDINGS, INC.

BPTH · Pharmaceutical Preparations

Passage BIO, Inc.

PASG · Biological Products, (No Diagnostic Substances)

Jade Biosciences, Inc.

JBIO · Pharmaceutical Preparations

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

Coya Therapeutics, Inc.

COYA · Pharmaceutical Preparations

: 11/08/2026